Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Scenario drafting to anticipate future developments in technology assessment.

BMC research notes - 16 Aug 2012

Retèl Valesca P, Joore Manuela A, Linn Sabine C, Rutgers Emiel J T, van Harten Wim H

Abstract excerpt

BACKGROUND: Health Technology Assessment (HTA) information, and in particular cost-effectiveness data is needed to guide decisions, preferably already in early stages of technological development. However, at that moment there is usually a high degree of uncertainty, because evidence is limited a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cost-Benefit Analysis
Share to Decision Support Techniques
Share to Diffusion of Innovation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Health Care Costs

Share to Models, Economic

Share to Practice Guidelines as Topic

Share to Quality-Adjusted Life Years

Share to Uncertainty

Source

Open in PubMed Open full text

Identifiers

PMID: 22894140
DOI: 10.1186/1756-0500-5-442
PMCID: PMC3444406

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-22894140-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 11 closest

Scenario drafting to anticipate future developments in technology assessment.PMID 22894140Read ↗

Scenario drafting for early technology assessment of next generation sequencing in clinical oncology.Semantic proximity Read ↗

Cost-effectiveness analysis of the 70-gene signature compared with clinical assessment in breast cancer based on a randomised controlled trialSemantic proximity Read ↗

Genomic profile of breast cancer: cost-effectiveness analysis from the Spanish National Healthcare System perspective.Semantic proximity Read ↗

Cost-utility analysis of genomic profiling in early breast cancer in ColombiaSemantic proximity Read ↗

The costs and benefits of an early access scheme for oncology medicines in IrelandSemantic proximity Read ↗

Adaptive health technology assessments to inform oncology based priority setting in IndiaSemantic proximity Read ↗

How the HTAR will contribute to a value-based decision making for medicinal products across the EUSemantic proximity Read ↗

Population-Based Study to Determine the Health System Costs of Using the 21-Gene Assay.Semantic proximity Read ↗

The value of innovation in breast cancer treatment: real option value of olaparib for first-line treatment of gBRCA-mutated HER2 negative metastatic breast cancer.Semantic proximity Read ↗

Patient preferences for gene therapy in haemophilia: Results from the PAVING threshold technique surveySemantic proximity Read ↗

Decision support for health care: the PROforma evidence base.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.